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ABSTRACT:
Medulloblastoma is the most common malignant brain tumor of childhood, and 
represents a significant clinical challenge in pediatric oncology, since overall survival 
currently remains under 70%. Patients with tumors overexpressing MYC or harboring 
a MYC oncogene amplification have an extremely poor prognosis. Pharmacologically 
inhibiting MYC expression may, thus, have clinical utility given its pathogenetic role in 
medulloblastoma. Recent studies using the selective small molecule BET inhibitor, JQ1, 
have identified BET bromodomain proteins, especially BRD4, as epigenetic regulatory 
factors for MYC and its targets. Targeting MYC expression by BET inhibition resulted 
in antitumoral effects in various cancers. Our aim here was to evaluate the efficacy of 
JQ1 against preclinical models for high-risk MYC-driven medulloblastoma. Treatment 
of medulloblastoma cell lines with JQ1 significantly reduced cell proliferation and 
preferentially induced apoptosis in cells expressing high levels of MYC. JQ1 treatment 
of medulloblastoma cell lines downregulated MYC expression and resulted in a 
transcriptional deregulation of MYC targets, and also significantly altered expression 
of genes involved in cell cycle progression and p53 signalling. JQ1 treatment prolonged 
the survival of mice harboring medulloblastoma xenografts and reduced the tumor 
burden in these mice. Our preclinical data provide evidence to pursue testing BET 
inhibitors, such as JQ1, as molecular targeted therapeutic options for patients with 
high-risk medulloblastomas overexpressing MYC or harboring MYC amplifications.
INTRODUCTION
Tumors originating in the central nervous system 
(CNS) are the second most prevalent cancers and the 
leading cause of cancer-related mortality in childhood 
[1]. Medulloblastoma is the most common malignant 
brain tumor in children and still presents a significant 
challenge to treat, with an overall survival under 70% 
[2]. Four subgroups with distinct clinical, biological 
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and genetic profiles are now recognized, namely, WNT, 
SHH, group 3 and group 4 [3]. WNT as well as Group 3 
tumors express high MYC levels [3]. Group 3 is the most 
aggressive subgroup and typically expresses the highest 
MYC levels, with MYC amplifications occurring almost 
exclusively in this subgroup [4-6]. This most aggressive 
form of medulloblastoma portends a dismal prognosis, 
and generates a high proportion of aggressive, invasive 
and metastasizing tumors [4, 5, 7, 8]. Group 3 tumors are 
usually resistant to even multimodal treatment consisting 
of surgery, radiotherapy and chemotherapy. Thus, the 
integration of molecular targeted therapies into current 
treatment protocols and adjustment of conventional 
treatment is urgently needed to improve survival in 
patients with high-risk medulloblastoma without 
compromising long-term quality of life after treatment. As 
high-level MYC expression may drive the most aggressive 
characteristic of medulloblastomas, targeted inhibition of 
MYC should have clinical utility.
Posttranslational histone modifications are crucial 
for the modulation of chromatin structure and regulation 
of transcription [9]. Deregulation of these epigenetic 
modifications is common among cancer cells, and can 
lead to overexpression of oncogenes [10]. Bromodomains 
recognize acetylated lysines in the N-terminal regions 
of histones and, thus, function as chromatin readers [11] 
within the read-write-erase concept for the transfer of 
epigenetic information. Proteins containing reader domains 
recruit enzymes that add or remove posttranslational 
modifications, the writers and erasers, respectively, to the 
chromatin at areas of lysine modification. The BET protein 
family contain tandem bromodomains and an extraterminal 
or ET domain [12]. Human BET family members include 
BRD2, BRD3, BRD4 and BRDT [12]. BRD2, BRD3 and 
BRD4 are ubiquitously expressed, whereas, BRDT is 
localized primarily to the testis [13]. The BRD2 and BRD3 
proteins have been shown to regulate the transcription of 
growth-promoting genes such as CCND1, suggesting that 
they have reinforcing roles on controlling proliferative 
expansion [14]. BRD4 is a well-established regulator of 
the positive transcription elongation factor b (P-TEFb), a 
complex consisting of cyclin-dependent kinase 9 (CDK9) 
and cyclin T, among other polypeptides [15]. Through its 
interaction with BRD4, P-TEFb is recruited to promoters 
to phosphorylate the carboxy-terminal domain of the 
large subunit of RNA polymerase II. Functional studies 
have suggested that BRD4 plays an important role in 
regulating growth-associated genes at the M/G1 boundary 
by retaining P-TEFb at the promoters of key regulatory 
genes throughout mitosis [16, 17]. Furthermore, P-TEFb 
is recruited to MYC and MYC target gene promotors as 
an important step for MYC-dependent stimulation of 
response genes. One such response gene is CAD, which 
encodes a protein containing the first three enzyme 
activities of pyrimidine nucleotide biosynthesis, carbamyl 
phosphate synthetase II, aspartate transcarbamylase and 
dihydro-orotase [18, 19]. In summary, BET proteins play 
an important role in controlling proliferation and cell cycle 
progression, making them interesting targets for cancer 
therapy.
Several reports in the last two years have 
demonstrated antitumorigenic activities of the small 
molecule BET bromodomain inhibitor, JQ1, in preclinical 
models of hematological malignancies and neuroblastoma 
[20-22]. JQ1 binds competitively to bromodomains to 
displace them from acetylated histones, and shows highest 
potency and specificity towards BRD4, with weaker 
binding to BRD2, BRD3 and BRDT [23]. Intriguingly, 
BRD4 was shown to bind to histones in the MYC promoter 
region itself and play a critical role in MYC expression in 
human cancer cells such that inhibition of BET with JQ1 
resulted in a remarkable diminution of MYC expression, 
decreased BRD4 binding to the MYC promotor and 
associated cell death [20, 21]. Inhibition of the BRD4 
protein by JQ1, thus, proved to have effective antitumoral 
properties, suggesting that targeting MYC expression is 
feasible in selected cancers [20, 21].
With the aim of exploring molecular targeted 
therapeutic options for high-risk medulloblastomas, 
we analyzed whether inhibiting BET bromodomain 
proteins, and thereby targeting MYC and its target 
genes, could be effective against preclinical models of 
medulloblastoma. We hypothesized that especially high-
risk medulloblastomas, which overexpress MYC, could 
benefit from BET inhibition. To provide proof-of-principle 
that BET inhibition is therapeutically useful against 
medulloblastoma, we assessed the efficacy of JQ1 against 
medulloblastoma cells grown in cell culture models and as 
xenografts in nude mice.
RESULTS
BRD4 is expressed in primary medulloblastomas 
and human medulloblastoma cell lines
BRD4 was previously shown to be the most 
sensitive of all BET proteins to JQ1 treatment in in 
vitro pharmacological assays. We therefore assessed 
BRD4 expression in primary medulloblastomas and 
normal cerebellar tissue, as a control. BRD4 was 
immunohistochemically detected in samples from 115 
primary medulloblastomas from pediatric patients, 14 
cerebellum samples previously arrayed into a tissue 
microarray and 2 samples from primary medulloblastomas 
from adult patients. High-level BRD4 expression were 
detected in 99 of 115 pediatric primary medulloblastomas 
(75%) and in both adult medulloblastoma samples (Fig. 
1A, I-III). BRD4 was only marginally (22%) expressed in 
normal cerebellar tissue (Fig. 1A, IV and supplementary 
Fig. 1). We also evaluated BRD4 expression in a panel 
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of medulloblastoma cell lines that included HD-MB3, 
ONS-76, UW-228, Daoy, D-341 and D-283. All cell 
lines strongly expressed BRD4 (Fig.1 B), except for 
Daoy, which expressed lower BRD4 levels. Robinson, 
et al. previously published global mRNA expression 
profiles from 76 primary medulloblastomas and 9 normal 
cerebellar samples performed on Affymetrix chips [24]. 
We re-analyzed these data, and detected significantly 
higher BRD3 expression levels in medulloblastomas 
compared to normal human cerebellum (P <0.01). 
BRD2 and BRD4 were both expressed in all primary 
medulloblastomas in this medulloblastoma cohort, 
however, expression was not significantly higher than 
in cerebellar tissue. Taken together, BRD2, BRD3 and 
BRD4 are expressed in primary medulloblastomas. All 
medulloblastoma subgroups strongly expressed BRD4, 
with the highest expression detected in the shh subgroup 
(see supplementary Fig. 2). While expression of only 
BRD3 was elevated in tumors from the cohort analyzed, 
BRD4 expression was significantly higher in tissue 
samples from a separate medulloblasoma cohort as well 
as in cell lines derived from human medulloblastomas, 
indicating that mRNA expression may not be the best 
measure of protein activity and targetability in this case. 
The one prerequisite for our study assessing JQ1 efficacy 
against medulloblastoma, that its primary target be 
expressed, was fulfilled not only in our preclinical models 
but also in primary medulloblastoma samples.
JQ1 reduces cell viability and proliferation and 
induces apoptosis and senescence in human 
medulloblastoma cell lines
To investigate the impact of JQ1 treatment on 
typical tumorigenic properties, we assessed viability, 
proliferation, apoptosis and senescence in the 
medulloblastoma cell lines, HD-MB3, Daoy, UW-228, 
ONS-76, D-283 and D-341, in culture. MTT assays were 
conducted after 48-120h of JQ1 treatment to assess cell 
viability. JQ1 treatment significantly reduced viabiltiy 
in medulloblastoma cells in culture (Fig. 2 A-C). Fifty 
percent inhibition of growth (IC50) in our cell line panel 
was observed at JQ1 concentrations between 78nM and 
>1µM (Fig. 2A). Lowest IC50 values occurred primarily 
after 72h of treatment. Interestingly, the MYC-amplified 
HD-MB3 cell line was among the most sensitive to JQ1 
treatment. The Daoy and UW-228 cell lines were least 
sensitive to JQ1 with IC50 values well above 1µM. 
In comparison to the other cell lines, Daoy and UW-
228, harbor TP53 mutations. Previous studies using 
RNAi showed that the BET family member, BRD4, 
is required for transition through the cell cycle [16]. 
Consistent with this observation, cell cycle analysis in 
our medulloblastoma cell line panel revealed an increase 
in the percentage of cells in G1 after JQ1 exposure (Fig. 
2D). These data suggest that BET bromodomain inhibition 
perturbs cells at the G1/S border. Treatment with JQ1 
also increased the population of sub-G1 cells, suggesting 
that JQ1 induces apoptosis in a fraction of cells in the 
population (Fig. 2D). Analysis of treated cells using the 
cell death detection ELISATM produced similar findings. 
The fraction of apoptotic cells was significant higher 
after JQ1 treatment in all cell lines except D-283 (Fig. 
2E). JQ1 produced the strongest apoptotic response in 
the MYC-amplified cell lines, HD-MB3 and D-341. JQ1 
treatment also enhanced cell senescence in most of the six 
medulloblastoma cell lines (Fig. 2F). Cell proliferation 
was analyzed using BrdU incorporation 72h after 
treatment, and showed significantly reduced proliferative 
capacity in most of the six medulloblastoma cell lines 
after JQ1 treatment (Fig. 2G). Taken together, the BET 
bromodomain inhibitor, JQ1, induces cell cycle arrest, 
senecence and apoptosis with a range of sensitivity across 
a panel of medulloblastoma cells.
Figure 1: BRD4 is expressed in primary 
medulloblastomas and medulloblastoma cell lines. 
A. BRD4 expression was immunohistochemically analyzed in 
primary medulloblastomas from 115 pediatric and 2 adult patients 
and in 14 samples of normal cerebellum as a control tissue. Four 
exemplary pictures of BRD4 staining in medulloblastomas 
and normal human cerebellum are shown: I-II from pediatric 
medulloblastomas, III from an adult medulloblastoma and IV 
from cerebellum. B. BRD4 protein expression was analyzed 
in western blots of whole-cell lysates from a panel of human 
medulloblastoma cell lines. HD-MB3 and D-341 harbor MYC 
amplifications and UW-228 as well as Daoy harbor TP53 
mutations. β-actin was used as a loading control.
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JQ1 treatment deregulates MYC and MYC target 
expression in medulloblastoma cell lines 
We next examined the effect of BET inhibitors 
on MYC functionality in several genetic backgrounds 
relevant for human primary medulloblastoma. We used 
the two MYC-amplified cell lines, HD-MB3 and D-341, 
along with three cell lines (ONS-76, Daoy, and D-283) 
Figure 2: JQ1 treatment reduces viability of medulloblastoma cells. A. Absolute IC
50 
values of all six cell lines at different time 
points after treatment wich JQ1. B. Images taken from cells treated with JQ1 at IC
50
 concentration or with DMSO (control). C. Exemplary 
dose-response curve for HD-MB3 cells treated with JQ1 for 96h is shown. D. Fraction of cells in each point of the cell cycle measured after 
72h of treatment with 500nM JQ1 or DMSO (control). E. Cell death ELISA after 72h of treatment with 500nM JQ1 or DMSO (control). F. 
Scenescent cell fraction measured by ß-Gal activity after 72h of treatment with 500nM JQ1 or DMSO (control). G. BrdU ELISA performed 
after treatment of all medulloblastoma cell lines with 500nM JQ1 or DMSO (control) for 72 h.
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lacking MYC amplifications and one cell line (UW-228) 
that chronically expresses low MYC levels to model three 
genetic backgrounds, and measured MYC and MYC target 
gene expression using real-time RT-PCR. JQ1 treatment 
reduced MYC transcript levels in all cell lines regardless 
of MYC status (Fig. 3A and 3B). MYC expression was 
reduced by over 80% in the MYC-amplified cell line, 
HD-MB3 (Fig. 3A and 3B). The reduction in MYC 
transcript levels in cell lines treated with BET inhibitor 
was also recapitulated at the protein for MYC (Fig. 3C). 
Since MYC is known to drive proliferative activity, 
transcriptional reprogramming via MYC suppression 
may significantly contribute to the growth inhibitory 
effects mediated by BET bromodomain inhibition. 
MYC is known to interact with the CAD promotor and 
increase expression of CAD, which encodes enzymes for 
pyrimidine nucleotide biosynthesis [19]. We assessed 
MYC, CAD expression using real-time RT-PCR in time 
course in HD-MB3 cells treated with JQ1 to evaluate 
the temporal relationship between MYC suppression and 
CAD downregulation in cell lines treated with JQ1. MYC 
expression declined from 6h to 24h, where it reached its 
low point, and then recovered slightly to an intermediate, 
but significantly reduced level (Fig. 3B). This slight 
Figure 3: JQ1 treatment induces downregulation of MYC and its targets as well as of genes involved in cell cycle 
progression (cyclin D1 and E2F1). A. Analysis of MYC expression using real-time RT-PCR in all 6 medulloblastoma cell lines after 
24h of treatment with 500nM JQ1. Analysis of MYC (B) and the MYC target gene, CAD (D), as well as CCND1 (E) expression after 
a time course of 6-96h of JQ1 treatment (500 nM) using real-time RT-PCR. C. Expression of MYC as well as proteins selected from 
significantly affected genes in the expression array (cyclin D1 and E2F1, see Fig. 4) was assessed by western blotting of whole-cell lysates 
of medulloblastoma cell lines treated with 500nM JQ1 or DMSO control for 72h.
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recovery may be due to known autoregulatory feedback 
circuits of MYC [25]. CAD expression was also initially 
repressed, and mirrored the constant MYC decline from 
6h to 24h, but then recovered almost to control level 
expression by 96h (Fig. 3D). Considering the observed 
defects in cell cycle progression at G1/S border we also 
analysed CCND1 expression in time course. In contrast 
to MYC and CAD, CCND1 was repressed with a slight 
delay, beginning at 12h, but was continuously repressed 
to approximately 10% of control cells by 72h, where it 
remained for the rest of the time course (Fig. 3E). These 
observations support MYC downregulation as a primary 
effector of growth inhibition by BET inhibition in MYC-
driven tumor cells. 
Figure 4: Treatment with JQ1 deregulates gene expression of MYC target genes as well as genes involved in cell cycle 
and p53 pathways. A. Heatmap representation of the top 30 down- (blue) and up-regulated (red) genes (p < 0.001) in the HD-MB3 
human medulloblastoma cell line following 24h treatment with 500nM JQ1. Data are presented in row-normalized form, with a range 
with ±3 standard deviations from median expression. B. The top 6 pathways deregulated by JQ1 treatment of HD-MB3 cells. C. Gene 
set enrichment analysis (GSEA) of JQ1-mediated expression changes in HD-MB3 cells, showing deregulation of a set of genes involving 
MYC (DANG_MYC_TARGETS_UP and SCHUMACHER_MYC_TARGETS_UP), TP53 (V_p53_DECAMER_Q2) , cell cycle (KEGG_
CELL_CYCLE_886) and E2F (V_E2F_Q2). D. Expression differences in the MYC, CCND1, E2F1 and E2F2 genes in JQ1-treated and 
control (DMSO) cells are shown as box-plots.
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JQ1 affects components of the p53 pathway and 
cell cycle control elements
Given the broad activity of JQ1 in medulloblastoma 
cells, we sought to identify potential mechanisms that 
could explain these phenotypic responses. We performed 
expression profiling of HD-MB3 cells lines treated with 
JQ1 or DMSO control medium using Affymetrix arrays. 
Cells were treated for 24h with 500nM JQ1 to identify 
early, and potentially direct, transcriptional targets of 
JQ1 treatment. Data were normalized, then the average 
differential expression score from the data was used 
to determine genes affected by JQ1 treatment. A total 
of 239 and 474 genes were up- and downregulated 
(p-value < 0.001 and pfp < 0.05), respectively, after JQ1 
treatment. The top 50 differentially up- and downregulated 
genes are depicted in the heatmap (Fig. 4A). Using R2 
Database (http://hgserver1.amc.nl/cgi-bin/r2/main.cgi), 
we compared most deregulated genes upon (+)-JQ1 
treatment with a set of KEGG-Pathways to find pathways 
most significantly enriched with those genes. 368 out of 
2787 pathways met our criteria of t-test p < 0.001. The 
top 3 pathways identified in this analysis were DNA 
replication, cell cycle and the p53 pathway, with a 32-47% 
overlap and p<2.8e-08 (Fig. 4B). Next we used GSEA 
to assess the effects of JQ1 on transcriptional programs 
regulated by MYC, the E2F family, cell cycle and TP53. 
We interrogated our data for the statistically significant 
enrichment of published, validated gene signatures. The 
majority of gene sets associated with MYC, cell cycle, the 
E2F family and TP53 were statistically enriched among 
the genes that were downregulated by BET inhibition 
in HD-MB3 cells (Fig. 4C). As medulloblastoma cell 
lines harboring TP53 mutations were less responsive 
towards JQ1 treatment than those with wildtype TP53, 
we further investigated the functional implication of 
TP53 status for JQ1 efficacy. We generated the HD-MB3-
p53DN cell line, and treated these with JQ1. Sensitivity 
to JQ1 was diminished by enforced expression of the 
dominant-negative TP53 (Fig. 5A). Furthermore, enforced 
expression of the dominant-negative TP53 mutant 
completely abolished the ability of JQ1 (500nM, 72h) to 
induce apoptosis (Fig. 5B). These findings further support 
the functional importance of TP53 status for JQ1 efficacy 
in medulloblatoma cells. 
A number of key G1-associated cell cycle genes 
were deregulated in HDMB-3 cells after 24h of JQ1 
treatment. This result is consistent with our observation 
of defective cell cycle progression in JQ1-treated 
medulloblastoma cell lines (Fig. 2D) as well as the 
dramatic supression of CCND1 expression in HD-MB3 
cells treated in time course (Fig. 3E). Taken together, 
our data support that JQ1 treatment deregulates the MYC 
program as well as the cell cycle and p53 pathways in 
medullloblastoma cells. 
BRD4 knockdown phenocopies the effects of JQ1 
treatment in medulloblastoma cells
Previous studies have focused on the role of the 
specific BET family member, BRD4, which is most 
selectively inhibited by JQ1. Moreover, a recent siRNA 
screen to identify synthetic lethal interactions with MYC 
overexpression revealed BRD4 as a candidate gene [26]. 
Therefore, we transiently transfected the HD-MB3 cell 
line with two siRNAs directed against BRD4 or with 
transfection control alone and examined the effect of 
BRD4 knockdown on the same tumorigenic parameters 
we assessed after JQ1 treatment. A significant knockdown 
of BRD4 was achieved on both the mRNA and protein 
levels 72h after transfection (Fig. 6A+B). As we observed 
following JQ1 treatment, BRD4 knockdown resulted in a 
Figure 5: Enforced expression of a dominant-negative TP53 mutant abrogates the JQ1 effect. A. HD-MB3 cells stably 
transfected with a dominant-negative TP53 mutant (HD-MB3-p53DN) or parental cell line with wt p53 were treated with the JQ1 
concentrations indicated for 72h, then viability was assessed by MTT assay. B. The cell lines described in A were treated with either 500nM 
JQ1 or DMSO control for 72h, then the fraction of apoptotic cells was measured with the cell death ELISA. 
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downregulation of MYC mRNA and protein expression 
in real-time RT-PCR and western blots, respectively 
(Fig. 6A+B). Cell viability of HD-MB3 was significantly 
reduced and the fraction of apoptotic cells was elevated 
after transfection with both siRNAs (Fig. 6C+D). The 
siRNA siBRD4(2) more effectively knocked down BRD4 
expression on protein level than siBRD4(1). We, therefore, 
decided to monitor cells transfected with siBRD4(2) or 
control siRNA for 190h using the Xcelligance system. 
HD-MB3 cells transfected with siBRD4(2) proliferated 
more slowly than cells transfected with control siRNA 
(Fig. 6C). Taken together, BRD4 knockdown reduced 
both MYC expression and viability in the group 3-derived 
medulloblastoma cell line, HD-MB3, and therefore, 
phenocopies the effects of JQ1 treatment.
JQ1 has antitumoral activity against human 
medulloblastoma xenografts in mice
To further investigate the antitumor effects of BET 
inhibition in vivo, we explored a xenograft model of 
high-risk medulloblastoma. We used the most recently 
established group 3 cell line, HD-MB3, to recapitulate 
the tumor biology of this subgroup as closely as possible. 
HD-MB3 cells were injected subcutaneously into the 
flanks of immunocompromised mice. After palpable 
xenograft tumors were established, JQ1 was administered 
intraperitoneally to 7 mice once a day at 50 mg/kg body 
weight for a total of 28 days or until tumor size exceeded 
1000mm3. A cohort of 7 mice harboring xenograft tumors 
were injected with vehicle alone in the same injection 
Figure 6: siRNA-mediated BRD4 knockdown phenocopies JQ1 effects in HD-MB3 cells A. Protein expression in western 
blots is shown for HD-MB3 cells, which harbor a MYC amplification, 48h after either mock transfection (mock) or transfection with a control 
siRNA or an siRNA specific for BRD4 (siBRD4). B. Real-time RT-PCR of BRD4 expression in HD-MB3 cells 48h after transfection with 
a control siRNA or an siRNA specific for BRD4 (siBRD4). C. Proliferation of cells monitored for 8 days in real time using the Xcilligance 
system after siRNA-mediated BRD4 knockdown compared with cells transfected with control siRNA.
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regimen. Tumors grew significantly slower in JQ1-treated 
mice compared with vehicle-treated controls (Fig. 7A). 
Kaplan-Meier analysis showed that tumor growth to 
an average of 1,000 mm3 was delayed by 8 days in the 
treatment group compared with the vehicle control group 
(Fig. 7B). Thus, JQ1 treatment led to a highly significant 
increase in survival in the treatment group (Fig. 7B). One 
of 7 mice in the treatment group was euthanized because of 
a bleeding tumor at day 15 of treatment and was, therefore, 
omitted from Kaplan-Meier analysis. The average tumor 
Figure 7: JQ1 treatment significantly prolonged survival and decreased tumor volume in mouse medulloblastoma 
xenografts. A. Tumor volume of subcutaneous xenografts of MYC-amplified HD-MB3 cells in nu/nu mice treated with JQ1 (50mg/kg 
body weight per day) or control (DMSO). Black arrow indicates beginning of JQ1 treatment. B. Kaplan-Meier analysis of JQ1-treated and 
control mouse cohorts. C. Box-plots show tumor volume after 14 days of treatment. D. Western blots show MYC and BRD4 expression 
in xenograft tumors, with β-actin used as a loading control. Protein expression is shown for all 3 tumors each from mice treated with JQ1 
(50mg/kg BW) or DMSO for 2 days twice dayly. Bar graph shows mean (± S.D.) MYC expression measured in the 3 tumors by RT-PCR. 
E+F. Plots represent quantified expression of cleaved caspase 3 to identify apoptotic cells (p<0.05) or Ki67 to identify proliferating cells 
(p<0.05) from immunohistochemically stained xenograft tumors treated as described in D with JQ1 or DMSO. Selected micrographs show 
representative immunostaining in addition to hematoxylin & eosin staining (HE) for all 6 xenograft tumors. 
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volume was significantly smaller in the JQ1-treated group 
from day 4 onward to day 14 (Fig. 7C). Intensified JQ1 
treatment consistently downregulated MYC expression at 
both mRNA and protein levels in HD-MB3 tumors (Fig. 
7D). Immunohistological examination of xenograft tumors 
showed that JQ1 increased the number of apoptotic cells 
and reduced the number of proliferating cells in tumors 
(7E and 7F). These data demonstrate that BET inhibition 
results in significant in vivo antitumoral activity in high-
risk MYC-driven medulloblastoma.
DISCUSSION
Medulloblastoma is the most common brain tumor 
in children and arises from primitive neural cells of the 
cerebellum [1]. The majority of children with high-risk 
disease succumb to medulloblastoma despite intensive 
chemotherapy, surgery and radiation [2]. Moreover, 
surviving patients often suffer from long-term sequelae 
due to the aggressive treatment regimens. Targeted 
treatment approaches are, thus, clearly needed for these 
patients. The important role of the MYC oncogene in 
high-risk medulloblastoma tumorigenesis makes it a 
compelling, though until recently undruggable, target for 
drug development. Here we show that selectively targeting 
MYC using JQ1, a small molecule inhibiting BET 
bromodomains, displayed broad antineoplastic effects in 
medulloblastoma in vitro and in vivo. 
It was reported that siRNA knockdown of BRD4, 
the main target of JQ1, reduces expression of key G1- and 
growth-associated genes, leading to cell cycle arrest in 
G1 and apoptosis in HeLa cells [16]. The same effect was 
observed in previous studies examining the effect of BET 
inhibition in different cancer entities [20, 21, 27, 28]. Here 
we show that targeting BRD4 either pharmaceutically with 
JQ1 or by siRNA knockdown was effective at reducing 
the viability of medulloblastoma cell lines. As has been 
described before in cells derived from other tumor entities, 
we showed here that JQ1 induced medulloblastoma cells to 
accumulate in the G1 phase of the cell cycle. The highest 
incidence of apoptosis occurred in cells harboring MYC 
amplifications, namely HD-MB3 and D-341, indicating 
the importance of MYC status for JQ1 efficacy [29]. 
Interestingly, in cell lines in which JQ1 did not induce 
apoptosis, induction of senescence was observed. Cell 
lines differed considerably in respect to their sensitivity 
to JQ1. Until now, the capability and capacity to respond 
to JQ1 has primarily been attributed to the extent of 
endogenous MYC expression [28]. In glioblastoma though, 
Cheng et al (2013) postulated that p21 provided partial 
protection against JQ1 when genetically manipulated 
[27]. Interestingly, one cell line (Daoy) with only a minor 
response to JQ1 treatment in our study, expressed lower 
levels of BRD4 than the other cell lines. Inconsistant with 
the assumption that this lower BRD4 expression may 
be causal for the reduced sensitivity, Daoy exhibited the 
same level of MYC and MYC downregulation after JQ1 
treatment as cell lines which responded well to JQ1. The 
other cell line (UW-228) with a minor response to JQ1, did 
not express detectable MYC levels in western blots. Thus, 
poor JQ1 response in UW-228 can probably be attributed 
to the absence, at this level of detection, of the primary 
drug target from the cellular background. Interestingly, 
both the UW-228 and Daoy cell lines harbor TP53 
mutations. Combining these results with our expression 
profiling findings, we hypothesize that the mutant TP53 
could impede response to JQ1. To substantiate p53 
dependance of JQ1 effects, we showed that enforced 
expression of a dominant-negative TP53 mutant in a cell 
line formerly sensitive to JQ1 treatment impaired the JQ1 
effect. These results are concordant with observations 
recently published by Shwu-Yuan Wu et al., who described 
important interactions between BRD4 and TP53 [11]. 
They showed that BRD4 bound to and recruited TP53 
to promoters of genes known to be regulated by TP53. 
Fewer than 10% of sporadic medulloblastomas harbor 
TP53 mutations [30]. However, MDM2 amplification or 
overexpression, which increases TP53 degradation, is 
frequently observed in medulloblastomas with wildtype 
TP53 [31]. Based on these observations and previous 
work where we demonstrated that pharmacologically 
inhibiting MDM2 in medulloblastoma cells with wildtype 
TP53 reactivated p53 activity, it may be advantageous to 
investigate possible synergies between JQ1 and MDM2 
inhibitors, such as nutlin-3 [32]. As TP53 mutations are 
among the most recurrent alterations in human cancer 
entities, additional evidence of the dependence of the 
activity of BET inhibition on TP53 status should be further 
investigated in other tumor entities as well.
Looking at previous studies, BET inhibition appears 
to be highly selective and affect only a few genes. One 
compelling feature of JQ1 is the ability to effectively 
downregulate MYC [20], which is a gene long thought 
to be difficult if not impossible to target. JQ1 was highly 
effective against preclinical models of several types of 
cancers with recurrent MYC amplifications, including 
acute myeloid leukemia, Burkitt’s lymphoma and multiple 
myeloma, and efficacy was directly related to the extent 
of MYC suppression by treatment [20, 21]. Supporting 
these previous findings, medulloblastoma cells exhibited 
a similar reduction of MYC expression following BET 
inhibition here, and the strongest apoptotic induction 
occurred in MYC-amplified cell lines. We also observed 
downstream effects of MYC suppression. CAD, a gene 
known to be regulated by MYC and BRD4, expression 
was similarly downregulated after JQ1 treatment. This 
may have resulted from a direct inhibitory effect of JQ1 
on the interaction of BRD4 with the CAD promoter in 
addition to the secondary effect of MYC downregulation. 
Taken together, BET inhibition via JQ1 downregulates 
MYC as well as MYC targets in medulloblastoma cells. 
To gain further functional insight into the working 
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mechanisms of BET bromodomains, we performed 
expression profiling of medulloblastoma cells with and 
without JQ1 treatment. Gene set enrichment analysis using 
KEGG pathways revealed that targets affected by BET 
inhibition were involved in cell cycle progression, the p53 
pathway and DNA replication. This fits our observation 
that JQ1 appears to disrupt the cell cycle by inducing G1 
arrest and apoptosis. We also observed that expression 
of two key factors in G1 progression, cyclin D1 and 
E2F1, were repressed, mirroring the reduction in MYC 
expression, by JQ1 treatment. Since siRNA-mediated 
depletion of the BRD2 BET protein has been described 
to reduce transcription of cyclin D1 in human cells [14], 
we investigated the result of siRNA-mediated BRD4 
knockdown on CCND1 regulation in medulloblastoma 
cells. BRD4 knockdown reduced CCND1 expression 
similarly to JQ1 treatment. Although investigation into 
the mechanisms by which BRD4 influences cyclin D1 
expression was beyond the scope of this paper, further 
investigation of this interaction could be of clinical 
relevance, considering the importence of the cyclin D 
family in tumor maintenance [33]. Our findings suggest 
that not only MYC, but a variety of genes involved with the 
p53 pathway and in cell cycle control are affected by JQ1 
treatment. These results are concordant with previously 
published results for JQ1 action on neuroblastoma cells, 
which described supression of a variety of genes including 
the E2F family [28]. These new insights implicate the BET 
protein family in the fine control of cell cycle regulation 
and progression, emphasizing the benefit of further 
functional investigation of this family for tumorigenic 
control mechanisms.
With the aim to generate preclinical evidence 
for JQ1 efficacy in an animal model for high-risk 
medulloblastoma, we treated subcutaneous xenografts 
of cells derived from a group 3 medulloblastoma in 
nude mice with JQ1. Given that JQ1 has no difficulty 
passing the blood-brain barrier, JQ1 should have similar 
effects on tumors regardless of their localization, and not 
present a problem for reaching medulloblastoma in the 
brain. However, testing in orthotopic medulloblastoma 
models could provide additional preclinical information 
prior to entry into clinical trials. The HD-MB3 cell line 
is well-described and one of the few medulloblastoma 
cell lines originating from a MYC-amplified group 3 
tumor [34]. We only used this cell line, since this model 
is recently established, and is most probably the closest 
recapitulation of Group 3 medulloblastoma biology when 
compared to more established cell lines [34]. JQ1 potently 
inhibited xenograft tumor growth, using these cells, and 
significantly prolonged mouse survival. Similarly to our in 
vitro findings, JQ1 reduced MYC expression in xenograft 
tumors. Interestingly, JQ1 resulted in elevated BRD4 
protein expression in treated tumors. This observation 
may indicate that an endogenous feed-back loop could 
be initiated by BRD4 inhibition at least in some cellular 
backgrounds. To avoid such feedback mechanisms, further 
investigations about optimal dosing schedules for BET 
inhibitors might be conducted.  Our results give conclusive 
evidence that BET inhibition via JQ1 is effective in 
reducing medulloblastoma growth in a preclinical mouse 
model for high-risk medulloblastoma.
Future clinical testing of BET inhibitors in high-
risk medulloblastoma is clearly necessary to provide 
the ultimate proof of the usefulness of this therapeutic 
strategy for the treatment of this highly aggressive 
pediatric malignancy. Investigating possible synergies 
between BET inhibitors and other therapeutic agents 
in clinical use for medulloblastoma treatment should, 
therefore, be addressed in future studies. As mentioned 
above, combining BET inhibition with targeted therapies 
restoring TP53 expression, such as MDM2 inhibitors, 
could provide one possibly synergistic option. Many 
therapeutic strategies now used to treat medulloblastoma, 
such as radiation, induce DNA damage in tumor cells. 
DNA damage normally activates a signalling network 
that blocks cell cycle progression, recruits DNA repair 
factors or triggers senescence or apoptosis [35]. It is well 
established that this DNA damage response is abrogated 
in many malignancies in such a way that tumor cells 
manage to maintain their proliferative capacity [36]. 
BRD4 was recently shown to insulate chromatin from 
DNA damage signalling [37], indicating that combining 
DNA-damaging agents with BET inhibitors, such as JQ1, 
may increase DNA damage response in medulloblastoma 
cells. Exploring such putative synergies in clinical 
and preclinical investigations should fine-tune optimal 
conditions for JQ1 administration.
Intensive research in the past years has revealed 
BET bromodomain inhibition as a potent course of action 
to inhibit MYC and induce antitumoral effects in different 
malignancies [20-22, 27, 28]. Our observations explored 
the feasibility of treating high-risk medulloblastoma 
patients with JQ1 in preclinical models. The survival 
advantage observed in mouse xenograft models of high-
risk medulloblstoma suggests that JQ1 has the potential to 
generate a measurable response in this patient subgroup, 
which have dismal prognoses with current treatment 
regimens, and thus, should be considered for entry into 
clinical testing. 
MATERIAL AND METHODS
JQ1 treatment of cell lines in culture
The HD-MB3, ONS-76, DAOY and UW-228 
human medulloblastoma cell lines were grown in 
RPMI 1640 supplemented with 10% FCS, L-glutamine, 
and antibiotics [38].  Medium for HD-MB3 was also 
supplemented with 1% nonessential amino acid solution. 
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The human medulloblastoma cell lines, D-341 and D-283, 
were cultured in Eagle’s Minimum Essential Medium 
supplemented with 10% FCS and antibiotics. The identity 
of all cell lines was verified by STR genotyping performed 
by the German Collection of Microorganisms and Cell 
Cultures (DSMZ, Braunschweig, Germany). HD-MB3-
p53DN cells were generated by transfecting HD-MB3 with 
pMSCV-puro-p53DD (Addgene, #K1062-1, Cambridge, 
MA, USA), and selected for stable transfectants with 2 μg 
puromycin/ mL full medium. Pure (+)-JQ1 sterioisomer 
(BPS Bioscience, San Diego, CA, USA), which is referred 
to as JQ1 throughout this paper, was aliquoted for single 
use and stored at -20°C as stock solution (10 mM in 
DMSO). Cells were exposed to 0–6 µM JQ1, prepared as 
serial dilutions in full medium, for the periods indicated. 
The final dimethyl sulfoxide (DMSO) concentration was 
kept at or below 0.2%.
Real-time reverse transcriptase-PCR
Total RNA was isolated from cells using the 
RNeasyMini kit (Qiagen, Hilden, Germany), and cDNA 
synthesis was performed using the SuperScript reverse 
transcription kit (Invitrogen, Darmstadt, Germany). 
CAD, CCDN1 and MYC expression were monitored 
using Assays-on-Demand™ (Applied Biosystems, Foster 
city,CA, USA). Expression values were normalized to the 
geometric mean of GAPDH [39]. Data analysis and error 
propagation were performed using the qbasePLUS software 
version 1.5 (http://www.biogazelle.com).
Western blot analysis
Protein lysates were extracted from cells, separated 
on SDS-PAGE and electrotransferred as described in 
Cimmino et al. [40]. Membranes were blocked 1h with 
5% nonfat dry milk in TBS-T, then incubated with primary 
antibodies in 5% nonfat dry milk in TBS-T overnight or 
up to 24h at 4°C. Primary antibodies against the following 
proteins were used: MYC (1:1000, #9402, Cell Signaling, 
Danvers, MA, USA), BRD4 (1:200, H-250, sc-48772, 
Santa Cruz, Dallas, TX, USA), Cyclin D1 (1:200, 
H-295, sc-753, Santa Cruz), E2F1 (1:200, AF4825, R&D 
Systems, Minneapolis, MI, USA) and B-actin (1:2000, 
Sigma-Aldrich, St. Louis, MO, USA) as the loading 
control. After washing twice with TBS-T, membranes 
were incubated 1h at room temperature with secondary 
antibodies diluted 1:2000 in 5% nonfat dry milk in TBS-T. 
Horseradish peroxidase (HRP)-conjugated anti-rabbit 
IgG (GE Healthcare, Fairfield, USA) or HRP-conjugated 
anti-mouse IgG (GE Healthcare) were used as secondary 
antibodies. Proteins were visualized using the ECLplus 
western blotting detection kit (Amersham, Amersham, 
UK) and analyzed on a FusionFX7 detection device 
(Vilber Lourmat, Eberhartzell, Germany). 
Cell proliferation, death, viability, senencence and 
Cell cycle analysis
Medulloblastoma cell lines were seeded onto 96-
well plates (2 × 103 per well) in triplicate for all assays, 
and incubated for 24h to permit surface adherence. 
Viability was assessed in time course after treatment 
with 1nM-6µM JQ1 for 24, 48, 72 and 96h using the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay (Roche, Basel, Switzerland), 
according to the manufacturer’s protocol. The IC50 was 
calculated using GraphPad Prism 5.0 (GraphPad Software 
Inc., San Diego, CA, USA). Apoptosis, proliferation and 
senescence were assessed after identical time-course 
treatment with 500 nM JQ1 using the Cell Death and 
BrdU ELISAs (Roche) and the fluorometric SA-ß-gal 
activity assay (Cell Biolabs, San Diego, CA, USA), 
respectively. All assays were performed according to 
the manufacturer’s protocols. For cell cycle analysis, 
cell lines were cultured 48h with 500 nM JQ1 or DMSO 
control in 35mm plates at 5 x 107 cells/plates. Cells were 
removed by trypsinization and washed 3 times with PBS, 
then incubated with propidium iodide for 15 min to stain 
DNA. Cellular DNA content was analyzed in an FC500 
flow cytometer (Beckman Coulter). All experiments were 
independently performed at least 3 times, if not otherwise 
indicated.
BRD4 knockdown and Xcelligence viability assay 
To assess cellular survival after BRD4 knockdown, 
we transfected HD-MB3 cells with siRNA against BRD4. 
HD-MB3 cells were seeded at 5 x 104 on a 6-well plate 
and incubated for 24h. HD-MB3 cells were transiently 
transfected with either an siRNA directed against BRD4 
(siBRD4 (1), Cat. No. s23901, and siBRD4 (2), Cat. No. 
s23902, Ambion, Austin, TX, USA) or the scrambled 
control siRNA at a final concentration of 20 nmol using 
the Hiperfect transfection reagent (Qiagen, Hilden, 
Germany) according to the manufacturer`s protocol. 
Mock control using only transfection reagent was also 
performed. Protein and mRNA expression were analyzed 
using western blotting and real-time RT-PCR, respectively, 
as described above. Cell viability and cell death were 
analyzed after 72h of transfection by MTT assay and 
cell death ELISA as described above. Since siBRD4 (2) 
showed the most effective BRD4 knockdown, we assessed 
cellular survival after transfection with this siRNA in real 
time using the Xcelligence system (Roche). HD-MB3 
cells were plated in triplicate at 2 × 103 cells/well onto 96-
well Xcelligence microelectronic cell sensor plates, and 
cultured overnight in antibiotic-free complete media. Cells 
were transiently transfected with 20 nmol of either siBRD4 
or control siRNA or mock transfected, then adherence to 
the culture plates was continuously monitored for 190h to 
Oncotarget 2013; 4:2092www.impactjournals.com/oncotarget
assess cellular survival. 
Tissue microarrays and immunohistochemistry
Tissue microarrays were prepared from paraffin-
embedded tissue specimens from 115 primary 
medulloblastomas and 14 cerebellum samples [32]. For 
the array, 3 different tissue cores were taken from each 
formalin-fixed, paraffin-embedded tumor block using a 
manual device (Beecher Instruments, Sun Prairie, WI, 
USA), and 2µm sections were cut from the microarray for 
immunohistochemical analyses. Sections from 2 additional 
formalin-fixed paraffin-embedded human primary 
medulloblastoma samples (2µm) and the formalin-fixed, 
paraffin-embedded xenograft tumors (5µm) from JQ1-
treated and untreated nude mice were also analyzed 
immunohistochemically. Immunohistochemical staining 
was conducted as previously described [41]. In brief, 
formalin-fixed paraffin-embedded tissue sections were 
deparaffinized by routine techniques, and placed in 200 
µL of target retrieval solution (pH, 6.0; Envision Plus 
Detection Kit; Dako, Glostrup, Denmark) for 20 min at 
100°C. After cooling for 20 min, slides were quenched 
with 3% H2O2 for 5min before incubating with primary 
antibody using a Dako Autostainer (Dako Cytomation). 
Primary antibodies against BRD4 (1:200, sc-48772, 
Santa Cruz), cleaved caspase 3  (1:200, Cell Signaling) 
and Ki67 (1:25, DAKO) were used. BRD4 expression 
was evaluated by 2 independent researchers using a 
semiquantitative scoring system on microarrays. In brief, 
the number and intensity of positive cells were counted 
and scored between 0 and 3 (0, no positive nuclei; 1, 
1% - 20% nuclei display intense staining or more nuclei 
display weak staining; 2, 20% – 80% intense staining or 
more nuclei display moderate staining; 3, 80% – 100% 
nuclei display intense staining). Samples with scores of 
1 - 3 were considered as expressing the target protein. 
Affymetrix microarray analysis
HD-MB3 cells plated at 5 x 104 cells/well in 6-well 
plates, then after 12h for attachment, were treated in 
triplicate with medium containing 0.2% DMSO (control) 
or 500nM JQ1 for 24h. Total RNA was extracted using the 
RNeasyMini kit (Qiagen, Hilden, Germany), and used to 
confirm at least a 50% decrease in MYC expression in the 
JQ1-treated cells using real-time RT-PCR. Three replicas 
were treated and analyzed. Samples were profiled using 
the genechip Affymetrix Human Gene Expression Array 
(HG-U133 Plus 2.0, Affymetrix, Santa Clara, CA, USA) 
at the Centre for Medical Biotechnology at the University 
Hospital Essen using established protocols. Microarray 
.CEL files were normalized and summarized to gene levels 
to conduct gcRMA normalization using the Bioconductor 
repository of statistical tools [42]. Probes for which the 
log2 expression was < 4 in at least 5 of the 6 samples, were 
considered underexpressed and filtered out of the dataset. 
Expression data from a total of 23376 probes remained 
for analysis after filtering. Differential expression analysis 
was performed using the Rank Product analysis package 
v 2.13 in R [43]. Hierarchical clustering was performed 
on the Manhattan distance of log2 expression values for 
either all or the 100 most differentially expressed genes 
to visualize differential gene expression in HD-MB3 cells 
following JQ1 treatment. Gene set enrichment analysis 
was performed using the GSEA v2.0 software from www.
broadinstitute.org/gsea [44]. Genes were ranked using a 
signal:noise ranking metric (the difference of the means 
of the populations compared scaled by the standard 
deviation). The c2.cp.kegg.v3.1.symbols.gmt, c2.all.
v3.1.symbols.gmt and c5.all.v3.1.symbols.gmt (www.
broadinstitute.org/gsea) gene sets were used in this study. 
Statistical analysis
We used the R2 visualization and analysis platform 
(http://hgserver1.amc.nl/cgi-bin/r2/main.cgi) to re-analyze 
expression data from human primary medulloblastoma 
microarrays (Künkele et al. 2012) and analyze expression 
data from JQ1-treated and control HD-MB3 cells. SPSS, 
version 18.0 (IBM SPSS) was used for further statistical 
analysis. The student’s two-sided t-test was used to 
compare all interval variables, and the chi-square test 
was used for the comparison for all categorical variables. 
Graph Pad Prism 5.0 (GraphPad Software Inc.) was used 
to perform Kaplan-Meier survival analysis with log-rank 
statistics on treated and untreated mouse cohorts.
JQ1 treatment of xenograft tumors in nude mice
HD-MB3 medulloblastoma cells were cultured 
to 80% confluency, harvested and suspended in 200 µL 
Matrigel™ (BD Bioscience, Heidelberg, Germany) for 
subcutaneous inoculation (2 × 107 cells per mouse, n=14 
mice) into the left flank of 4-week-old female athymic 
(nu/nu) mice. Mice were randomly assigned to either 
JQ1 or vehicle control groups (n =7 mice per group) after 
tumors reached 150 – 200 mm3 in size. We used a JQ1 
treatment regimen previously been shown to be safe for 
control mice and effective against different malignancies 
in mouse models [21]. JQ1 or vehicle control was 
administered daily by intraperitoneal injection at a dose 
of 50mg/kg body weight. Tumor growth was monitored 
using a caliper and tumor volume was calculated using 
the formula (breadth × length × height)/2. Mice were 
euthanized by cervical dislocation when tumor size 
exceeded 1000mm3. In mice, whose xenograft tumors 
were to be examined for MYC downregulation, 4 doses of 
50 mg JQ1 per kg body weight were administered at 0, 12, 
24 and 36 h over a 2-day course. Mice were euthanized by 
Oncotarget 2013; 4:2093www.impactjournals.com/oncotarget
cervical dislocation 4 h after the last JQ1 dose. Xenograft 
tumors were excised from all mouse treatment cohorts, 
and divided into halves. Half the tissue was snap-frozen 
in liquid nitrogen then stored at -80°C and the other half 
was formalin-fixed and paraffin-embedded. All animal 
experiments were performed in accordance with the 
Council of Europe guidelines for accommodation and 
care of laboratory animals, and protocols were approved 
by the Ethical Commission for Animal Experimentation at 
the University Hospital Essen.
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